Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
1.
J Appl Toxicol ; 39(3): 485-497, 2019 03.
Artigo em Inglês | MEDLINE | ID: mdl-30345541

RESUMO

The benzoylurea chitin synthesis inhibitor teflubenzuron, widely used against sea lice in North Atlantic aquaculture, may pose an environmental threat to non-targeted crustaceans. In this experiment, laboratory acclimated pink shrimp (Pandalus montagui), a species found in fjords with Atlantic salmon farming, were exposed to dietary teflubenzuron for 46 days (control; low dose: 0.01 µg/g; high dose: 0.1 µg/g). The exposure doses represent 0.1% and 1% of a standard treatment dose for Atlantic salmon. Mortality and prevalence of deformities, pharmacokinetics, oxidative stress and transcriptomic and metabolomic profiling were used to assess the response to teflubenzuron exposure. Mortality in the high-dose group was 25% (five of 20 individuals). No control or low-dose group shrimps died. Phenotypic responses,i.e., leg deformities (0 control, 6 low, 8 high) and cloudy eyes (0 control, 3 low, 7 high), were observed in some surviving shrimps (control n = 15, low n = 17, high n = 15). Accumulated levels of teflubenzuron in shrimps from the high-dose group ranged from 4.7 to 369 ng/g wet weight. Transcriptomic profiling showed very few significantly altered genes in the exposed shrimps. Teflubenzuron-induced changes to the metabolome pointed to well-known effects of benzoylurea agents, with reduced levels of N-acetylglucosamine indicating an effect on chitin synthesis. The metabolomic profiling showed that teflubenzuron exposure was associated with reduced energy metabolism. Some metabolites pointed to increased necrosis and/or bacterial overgrowth in the teflubenzuron-exposed shrimps. In conclusion, this study shows that teflubenzuron causes phenotypic effects in P. montagui exposed to 0.1% of the treatment dose given to Atlantic salmon.


Assuntos
Benzamidas/toxicidade , Metaboloma/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Pandalidae/efeitos dos fármacos , Transcriptoma/efeitos dos fármacos , Aminoácidos/análise , Animais , Benzamidas/farmacocinética , Quitina/biossíntese , Metabolismo dos Lipídeos/efeitos dos fármacos , Pandalidae/metabolismo
2.
Ecotoxicol Environ Saf ; 160: 216-221, 2018 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-29807294

RESUMO

Infestations with salmon lice, a parasitic copepod, is a major problem in the salmon farming industry. Teflubenzuron is an in-feed pharmaceutical applied to control lice outbreaks; the standard medication is 10 mg per kg fish per day for seven days. Surveys reveal that teflubenzuron accumulates and persists in the sediment around fish farms and causes deformities and mortality in juvenile European lobster (Homarus gammarus), a species commonly found in the vicinity of salmon farms in Norway. To date, there is no information on sub-lethal effects of teflubenzuron on, for example, behavior. We conducted an experiment to assess possible difference in the shelter seeking behavior of teflubenzuron-exposed (N = 19) vs. not exposed (N = 19) H. gammarus juveniles. The teflubenzuron-exposed juveniles had been given very low concentrations, 1.7 µg per pellet twice per week for 113 days prior to this experiment. The concentration of teflubenzuron was estimated to be less than 1 ng/g lobster when they were tested in the behavior experiment. Animals were placed in a lane with a shelter at one end. Once a lobster had found and entered the shelter, they were repeatedly displaced back to the opposite end of the lane, for a total of 3 repeated runs per animal. Three of the exposed juveniles failed to settle in the shelter, and the remaining teflubenzuron-exposed animals took significantly more time to explore the environment and to find and recognize shelter. Furthermore, exposed lobsters also exhibited slower walking speed compared to the controls. These results demonstrate that teflubenzuron significantly reduces exploratory behavior, learning and activity of juvenile H. gammarus. Thus, exposure to teflubenzuron could increase predation mortality of juvenile lobsters in the wild.


Assuntos
Antiparasitários/toxicidade , Benzamidas/toxicidade , Nephropidae/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade , Animais , Aquicultura , Comportamento Animal/efeitos dos fármacos , Comportamento Exploratório/efeitos dos fármacos , Aprendizagem/efeitos dos fármacos , Nephropidae/fisiologia , Noruega
3.
mBio ; 8(6)2017 Dec 05.
Artigo em Inglês | MEDLINE | ID: mdl-29208749

RESUMO

Candida albicans remains the main etiologic agent of candidiasis, the most common fungal infection and now the third most frequent infection in U.S. hospitals. The scarcity of antifungal agents and their limited efficacy contribute to the unacceptably high morbidity and mortality rates associated with these infections. The yeast-to-hypha transition represents the main virulence factor associated with the pathogenesis of C. albicans infections. In addition, filamentation is pivotal for robust biofilm development, which represents another major virulence factor for candidiasis and further complicates treatment. Targeting pathogenic mechanisms rather than growth represents an attractive yet clinically unexploited approach in the development of novel antifungal agents. Here, we performed large-scale phenotypic screening assays with 30,000 drug-like small-molecule compounds within ChemBridge's DIVERSet chemical library in order to identify small-molecule inhibitors of C. albicans filamentation, and our efforts led to the identification of a novel series of bioactive compounds with a common biaryl amide core structure. The leading compound of this series, N-[3-(allyloxy)-phenyl]-4-methoxybenzamide, was able to prevent filamentation under all liquid and solid medium conditions tested, suggesting that it impacts a common core component of the cellular machinery that mediates hypha formation under different environmental conditions. In addition to filamentation, this compound also inhibited C. albicans biofilm formation. This leading compound also demonstrated in vivo activity in clinically relevant murine models of invasive and oral candidiasis. Overall, our results indicate that compounds within this series represent promising candidates for the development of novel anti-virulence approaches to combat C. albicans infections.IMPORTANCE Since fungi are eukaryotes, there is a limited number of fungus-specific targets and, as a result, the antifungal arsenal is exceedingly small. Furthermore, the efficacy of antifungal treatment is compromised by toxicity and development of resistance. As a consequence, fungal infections carry high morbidity and mortality rates, and there is an urgent but unmet need for novel antifungal agents. One appealing strategy for antifungal drug development is to target pathogenetic mechanisms associated with infection. In Candida albicans, one of the most common pathogenic fungi, morphogenetic transitions between yeast cells and filamentous hyphae represent a key virulence factor associated with the ability of fungal cells to invade tissues, cause damage, and form biofilms. Here, we describe and characterize a novel small-molecule compound capable of inhibiting C. albicans filamentation both in vitro and in vivo; as such, this compound represents a leading candidate for the development of anti-virulence therapies against candidiasis.


Assuntos
Antifúngicos/uso terapêutico , Benzamidas/uso terapêutico , Biofilmes/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Candida albicans/patogenicidade , Candidíase/tratamento farmacológico , Hifas/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/uso terapêutico , Animais , Antifúngicos/toxicidade , Benzamidas/toxicidade , Biofilmes/crescimento & desenvolvimento , Candida albicans/crescimento & desenvolvimento , Candidíase/microbiologia , Sobrevivência Celular/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Feminino , Hifas/crescimento & desenvolvimento , Camundongos , Camundongos Endogâmicos BALB C , Bibliotecas de Moléculas Pequenas/toxicidade , Virulência/efeitos dos fármacos , Fatores de Virulência
4.
Drug Chem Toxicol ; 39(1): 35-40, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26333298

RESUMO

The aim of this study was to evaluate the potential cytotoxic effects of Benodanil fungicide by employing both mitotic index (MI) and mitotic phases on the root meristem cells of Allium cepa and genotoxic effects by using in vitro micronucleus assay (MN) in human peripheral blood lymphocyte. In the Allium root growth inhibition test, the EC50 value was first determined as 25 ppm. Then, 2 × EC50 value (50 ppm), EC50 value (25 ppm), and 1/2 × EC50 value (12.5 ppm) were tested with different treatment periods (24, 48, and 72 h). Both negative and positive controls were also used in parallel experiments. We obtained that mitotic index and prophase index decreased when compared with the control in all concentrations. In the micronucleus assay, lymphocytes were treated with various concentrations (250, 500, 750, and 1000 µg/ml) of Benodanil for 24 and 48 h. The results showed that Benodanil did not induce MN frequency in all concentrations of both treatment periods. Additionally, it was determined that this pesticide decreased nuclear division index (NDI) significantly. It was concluded that Benodanil has a cytotoxic effects depending on decreasing of MI and NDI.


Assuntos
Benzamidas/toxicidade , Fungicidas Industriais/toxicidade , Linfócitos/efeitos dos fármacos , Benzamidas/administração & dosagem , Relação Dose-Resposta a Droga , Fungicidas Industriais/administração & dosagem , Humanos , Linfócitos/patologia , Testes para Micronúcleos , Índice Mitótico , Testes de Mutagenicidade , Cebolas/efeitos dos fármacos , Raízes de Plantas , Fatores de Tempo
5.
Aquat Toxicol ; 167: 143-56, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26318677

RESUMO

Increasing use of pharmaceutical drugs to delouse farmed salmon raises environmental concerns. This study describes an experiment carried out to elucidate the molecular mechanisms of the antiparasitic drug teflubenzuron on a non-target species, the European lobster. Juvenile lobsters (10.3±0.9 mm carapace length) were fed two environmentally relevant doses of teflubenzuron, corresponding to 5 and 20% of a standard salmon medication (10 mg/kg day), termed low and high dose in this study. After 114 days of dietary exposure, whole-animal accumulation of teflubenzuron was determined. One claw from each animal was collected for transcriptional analysis. Overall, exposed animals showed low cumulative mortality. Six animals, two from the low dose treatment and four from the high dose, showed exoskeletal abnormalities (claw deformities or stiff walking legs). Residual levels of teflubenzuron in juvenile lobster were 2.7-fold higher in the high dose (282 ng/g) compared to the low dose treatment (103 ng/g). The transcriptional examination showed significant effects of teflubenzuron on 21 out of 39 studied genes. At the transcriptional level, environmentally relevant levels of the anti-salmon lice drug impacted genes linked to drug detoxification (cyp3a, cyp6a2, cyp302a, sult1b1, abcc4), cellular stress (hsp70, hsp90, chh), oxidative stress (cat, gpx3) and DNA damage (p53), as well as molting and exoskeleton regulation (chi3l1, ecr, jhl1, chs1, ctbs, gap65, jhel-ces1) in claw tissue (muscle and exoskeleton). In conclusion, teflubenzuron at sub-lethal levels can affect many molecular mechanisms in European lobster claws.


Assuntos
Benzamidas/toxicidade , Regulação da Expressão Gênica/efeitos dos fármacos , Nephropidae/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade , Exoesqueleto/efeitos dos fármacos , Animais
6.
Aquat Toxicol ; 149: 8-15, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24555954

RESUMO

This study describes experiments carried out to examine effects of the antiparasitic drug teflubenzuron, used in delousing farmed salmon, on a non-target species, the European lobster (Homarus gammarus). Juvenile lobsters were fed two doses of teflubenzuron, 10 and 20mg/kg successively for 7 days corresponding to a standard medication of the fish (10mg/kg day) and twice the standard dose (20mg/kg day). Monitoring lasted 3 months to include at least one moulting period for all individuals. Cumulative mortality was higher in all replicates given medicated feed compared with the control group. Mean cumulative mortality for each dosing was 41 ± 13% for 10mg/kg and 38 ± 8% for 20mg/kg, i.e. no difference. Drug residue was analysed in all juveniles that died, in addition to 12 juveniles at day 8 and the first 12 surviving lobsters. A decline in concentration of teflubenzuron from over 8,000 ng/g (day 5) to 14 ng/g (day 70) was observed in the juveniles that died during the experiment. Twelve individuals that died contained 82 ng/g or less whereas the mean concentration in the first 12 lobsters that survived moulting was 152 ng/g. Following a single oral administration, the half-life of teflubenzuron in lobster was estimated to 3.4 days and the initial concentration (C0) to 515 ng/g at time t0. At the end of the study a considerable number of juvenile lobsters were observed with deformities in various organs; carapace, walking legs, cheliped, tail fan, abdomen and antenna. The occurrence of observed deformities varied from 0 to 15% in treated replicates and will most likely affect ability to locate and consume food (antenna, claw and walking legs), respiration (carapace) and ability to move/swim (walking legs, tail fan and abdomen). In total, the mortality and senescent damages were close to 50% in all replicates. Juveniles that survived medication without deformities however, moulted and increased in size at each moult equally well as the unmedicated controls.


Assuntos
Benzamidas/toxicidade , Nephropidae/efeitos dos fármacos , Poluentes Químicos da Água/toxicidade , Animais , Antiparasitários/metabolismo , Antiparasitários/toxicidade , Benzamidas/metabolismo , Meia-Vida , Nephropidae/anatomia & histologia , Nephropidae/crescimento & desenvolvimento , Análise de Sobrevida , Poluentes Químicos da Água/metabolismo
7.
Chemosphere ; 115: 54-8, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24560280

RESUMO

Imatinib mesylate (IM) is at present one of the most widely used cytostatic drugs in developed countries but information on its ecotoxicological activities is scarce. This article describes the results of the first investigation in which genotoxic and acute toxic properties of the drug were studied in higher plants. IM was tested in two widely used plant bioassays namely in micronucleus (MN) assays with meiotic tetrad cells of Tradescantia (clone #4430) and in mitotic root tip cells of Allium cepa. Additionally, acute toxic effects (inhibition of cell division and growth of roots) were monitored in the onions. Furthermore, we studied the impact of the drug on the fertility of higher plants in pollen abortion experiments with three wildlife species (Chelidonium majus, Tradescantia palludosa and Arabidopsis thaliana). In MN assays with Tradesacantia a significant effect was seen with doses ⩾10µM; the Allium MN assay was even more sensitive (LOEL⩾1.0µM). A significant decrease of the mitotic indices was detected at levels ⩾10µM in the onions and reduction of root growth with ⩾100µM. In the pollen fertility assays clear effects were observed at doses ⩾147.3mgkg(-1). Data concerning the annual use of the drug in European countries (France, Germany, Slovenia) enable the calculation of the predicted environmental concentration (PEC) values which are in the range between 3.3 and 5.0ngL(-1). Although comparisons with the genotoxic potencies of other commonly used cytostatic drugs and with highly active heavy metal compounds show that IM is an extremely potent genotoxin in higher plants, it is evident that the environmental concentrations are ⩾5 orders of magnitude lower as the levels which are required to cause adverse effects.


Assuntos
Benzamidas/toxicidade , Poluentes Ambientais/toxicidade , Mutagênicos/toxicidade , Piperazinas/toxicidade , Plantas/efeitos dos fármacos , Pirimidinas/toxicidade , Allium/efeitos dos fármacos , Allium/fisiologia , Arabidopsis/efeitos dos fármacos , Arabidopsis/fisiologia , Dano ao DNA/efeitos dos fármacos , Mesilato de Imatinib , Meristema/efeitos dos fármacos , Meristema/fisiologia , Testes para Micronúcleos , Cebolas/efeitos dos fármacos , Cebolas/fisiologia , Fenômenos Fisiológicos Vegetais/efeitos dos fármacos , Raízes de Plantas/efeitos dos fármacos , Raízes de Plantas/fisiologia , Pólen/efeitos dos fármacos , Pólen/fisiologia , Tradescantia/efeitos dos fármacos , Tradescantia/fisiologia
8.
Molecules ; 18(3): 3630-40, 2013 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-23519203

RESUMO

A series of novel N-phenylbenzamide derivatives were synthesized and their anti-EV 71 activities were assayed in vitro. Among the compounds tested, 3-amino-N-(4-bromophenyl)-4-methoxybenzamide (1e) was active against the EV 71 strains tested at low micromolar concentrations, with IC50 values ranging from 5.7 ± 0.8-12 ± 1.2 µM, and its cytotoxicity to Vero cells (TC50 = 620 ± 0.0 µM) was far lower than that of pirodavir (TC50 = 31 ± 2.2 µM). Based on these results, compound 1e is a promising lead compound for the development of anti-EV 71 drugs.


Assuntos
Antivirais/síntese química , Benzamidas/síntese química , Animais , Antivirais/farmacologia , Antivirais/toxicidade , Benzamidas/farmacologia , Benzamidas/toxicidade , Chlorocebus aethiops , Avaliação Pré-Clínica de Medicamentos , Enterovirus/efeitos dos fármacos , Concentração Inibidora 50 , Piperidinas/farmacologia , Piperidinas/toxicidade , Piridazinas/farmacologia , Piridazinas/toxicidade , Relação Estrutura-Atividade , Células Vero
10.
J Clin Invest ; 122(4): 1377-92, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22406537

RESUMO

In Alzheimer disease (AD), amyloid ß peptide (Aß) accumulates in plaques in the brain. Receptor for advanced glycation end products (RAGE) mediates Aß-induced perturbations in cerebral vessels, neurons, and microglia in AD. Here, we identified a high-affinity RAGE-specific inhibitor (FPS-ZM1) that blocked Aß binding to the V domain of RAGE and inhibited Aß40- and Aß42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. FPS-ZM1 was nontoxic to mice and readily crossed the blood-brain barrier (BBB). In aged APPsw/0 mice overexpressing human Aß-precursor protein, a transgenic mouse model of AD with established Aß pathology, FPS-ZM1 inhibited RAGE-mediated influx of circulating Aß40 and Aß42 into the brain. In brain, FPS-ZM1 bound exclusively to RAGE, which inhibited ß-secretase activity and Aß production and suppressed microglia activation and the neuroinflammatory response. Blockade of RAGE actions at the BBB and in the brain reduced Aß40 and Aß42 levels in brain markedly and normalized cognitive performance and cerebral blood flow responses in aged APPsw/0 mice. Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of Aß-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.


Assuntos
Doença de Alzheimer/prevenção & controle , Peptídeos beta-Amiloides/metabolismo , Benzamidas/uso terapêutico , Modelos Animais de Doenças , Fármacos Neuroprotetores/uso terapêutico , Fragmentos de Peptídeos/metabolismo , Receptores Imunológicos/antagonistas & inibidores , Envelhecimento/metabolismo , Doença de Alzheimer/genética , Doença de Alzheimer/metabolismo , Secretases da Proteína Precursora do Amiloide/antagonistas & inibidores , Peptídeos beta-Amiloides/genética , Animais , Benzamidas/farmacologia , Benzamidas/toxicidade , Barreira Hematoencefálica/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Células CHO/efeitos dos fármacos , Circulação Cerebrovascular/efeitos dos fármacos , Cricetinae , Cricetulus , Avaliação Pré-Clínica de Medicamentos , Humanos , Masculino , Camundongos , Camundongos Transgênicos , Fármacos Neuroprotetores/farmacologia , Fármacos Neuroprotetores/toxicidade , Fragmentos de Peptídeos/genética , Desempenho Psicomotor/efeitos dos fármacos , Receptor para Produtos Finais de Glicação Avançada , Proteínas Recombinantes de Fusão/metabolismo , Bibliotecas de Moléculas Pequenas
11.
Regul Toxicol Pharmacol ; 62(1): 115-24, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22210450

RESUMO

S-nitrosoglutathione reductase is the primary enzyme responsible for the metabolism of S-nitrosoglutathione (GSNO), the body's main source of bioavailable nitric oxide. Through its catabolic activity, GSNO reductase (GSNOR) plays a central role in regulating endogenous S-nitrosothiol levels and protein S-nitrosation-based signaling. By inhibiting GSNOR, we aim to increase pulmonary GSNO and induce bronchodilation while reducing inflammation in lung diseases such as asthma. To support the clinical development of N6022, a first-in-class GSNOR inhibitor, a 14-day toxicology study was conducted. Sprague-Dawley rats were given 2, 10 or 50 mg/kg/day N6022 via IV administration. N6022 was well tolerated at all doses and no biologically significant adverse findings were noted in the study up to 10 mg/kg/day. N6022-related study findings were limited to the high dose group. One male rat had mild hepatocellular necrosis with accompanying increases in ALT and AST and several male animals had histological lung assessments with a slight increase in foreign body granulomas. Systemic exposure was greater in males than females and saturation of plasma clearance was observed in both sexes in the high dose group. Liver was identified as the major organ of elimination. Mechanistic studies showed dose-dependent effects on the integrity of a rat hepatoma cell line.


Assuntos
Aldeído Oxirredutases/antagonistas & inibidores , Benzamidas/farmacocinética , Benzamidas/toxicidade , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/toxicidade , Pirróis/farmacocinética , Pirróis/toxicidade , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Asma/tratamento farmacológico , Benzamidas/sangue , Benzamidas/urina , Bile/química , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/sangue , Inibidores Enzimáticos/urina , Fezes/química , Feminino , Glutationa/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Pulmão/efeitos dos fármacos , Pulmão/patologia , Masculino , Pirróis/sangue , Pirróis/urina , Ratos , Ratos Sprague-Dawley
12.
Bioorg Med Chem Lett ; 21(19): 5849-53, 2011 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-21855338

RESUMO

The pyrrole based N6022 was recently identified as a potent, selective, reversible, and efficacious S-nitrosoglutathione reductase (GSNOR) inhibitor and is currently undergoing clinical development for the treatment of acute asthma. GSNOR is a member of the alcohol dehydrogenase family (ADH) and regulates the levels of S-nitrosothiols (SNOs) through catabolism of S-nitrosoglutathione (GSNO). Reduced levels of GSNO, as well as other nitrosothiols (SNOs), have been implicated in the pathogenesis of many diseases including those of the respiratory, cardiovascular, and gastrointestinal systems. Preservation of endogenous SNOs through GSNOR inhibition presents a novel therapeutic approach with broad applicability. We describe here the synthesis and structure-activity relationships (SAR) of novel pyrrole based analogues of N6022 focusing on removal of cytochrome P450 inhibition activities. We identified potent and novel GSNOR inhibitors having reduced CYP inhibition activities and demonstrated efficacy in a mouse ovalbumin (OVA) model of asthma.


Assuntos
Aldeído Oxirredutases/antagonistas & inibidores , Benzamidas/farmacologia , Sistema Enzimático do Citocromo P-450/metabolismo , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Imidazóis/síntese química , Imidazóis/farmacologia , Pirróis/farmacologia , Animais , Asma/tratamento farmacológico , Asma/enzimologia , Benzamidas/química , Benzamidas/toxicidade , Inibidores das Enzimas do Citocromo P-450 , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Esquema de Medicação , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/toxicidade , Humanos , Imidazóis/farmacocinética , Imidazóis/toxicidade , Pulmão/patologia , Pulmão/fisiopatologia , Camundongos , Estrutura Molecular , Terapia de Alvo Molecular , Nível de Efeito Adverso não Observado , Pirróis/química , Pirróis/toxicidade , Receptores Opioides delta/metabolismo , S-Nitrosoglutationa/metabolismo , Relação Estrutura-Atividade
13.
J Pharmacol Exp Ther ; 337(3): 775-85, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21406547

RESUMO

First-generation microsomal triglyceride transfer protein (MTP) inhibitors were designed to inhibit hepatic MTP and provide a novel treatment of dyslipidemia. Effective at lowering low-density lipoprotein-cholesterol (LDL-C), these inhibitors also elevate liver enzymes and induce hepatic steatosis in animals and humans. MTP is highly expressed in the enterocytes, lining the lumen of the jejunum, and is critical in the production of chylomicrons assembled from lipid/cholesterol and their transfer into systemic circulation. 6-(4'-Trifluoromethyl-6-methoxy-biphenyl-2-ylcarboxamido)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid phenyl ester (SLx-4090) (IC(50) value ∼8 nM) was designed to inhibit only MTP localized to enterocytes. In Caco-2 cells SLx-4090 inhibited apolipoprotein B (IC(50) value ∼9.6 nM) but not apolipoprotein A1 secretion. Administered orally to rats SLx-4090 reduced postprandial lipids by >50% with an ED(50) value ∼7 mg/kg. SLx-4090 was not detected in the systemic or portal vein serum of the animals (lower limit of quantitation ∼5 ng/ml) after single or multiple oral doses in fasted rodents. When coadministered with tyloxapol, SLx-4090 did not inhibit the secretion of hepatic triglycerides (TG), consistent with the absence of systemic exposure. Chronic treatment with SLx-4090 in mice maintained on a high-fat diet decreased LDL-C and TG and resulted in weight loss without the elevation of liver enzymes or an increase in hepatic fat. The compound did not result in toxicity when administered to rats for 90 days at a dose of 1000 mg/kg per day. These data support the concept that the inhibition of enterocytic MTP could serve as a useful strategy in the treatment of metabolic disorders.


Assuntos
Benzamidas/farmacologia , Proteínas de Transporte/antagonistas & inibidores , Hepatócitos/efeitos dos fármacos , Isoquinolinas/farmacologia , Reguladores do Metabolismo de Lipídeos/farmacologia , Fígado/efeitos dos fármacos , Animais , Apolipoproteína A-I/biossíntese , Apolipoproteínas B/metabolismo , Benzamidas/química , Benzamidas/farmacocinética , Benzamidas/toxicidade , Células CACO-2 , LDL-Colesterol/sangue , Avaliação Pré-Clínica de Medicamentos , Feminino , Hepatócitos/metabolismo , Humanos , Isoquinolinas/química , Isoquinolinas/farmacocinética , Isoquinolinas/toxicidade , Reguladores do Metabolismo de Lipídeos/química , Reguladores do Metabolismo de Lipídeos/farmacocinética , Reguladores do Metabolismo de Lipídeos/toxicidade , Fígado/metabolismo , Masculino , Camundongos , Camundongos Knockout , Permeabilidade/efeitos dos fármacos , Período Pós-Prandial , Ratos , Ratos Sprague-Dawley , Fatores de Tempo , Triazóis/farmacologia , Triglicerídeos/sangue
14.
J Pharmacol Toxicol Methods ; 56(2): 223-33, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17600733

RESUMO

INTRODUCTION: Drug-induced seizures are a serious, life-threatening adverse drug reaction (ADR) that can result in the failure of drugs to be licensed for clinical use or withdrawn from the market. Seizure liability of potential drugs is traditionally assessed using animal models run during the later phases of the drug discovery process. Given the low throughput, high animal usage and high compound requirement associated with these assays, it would be advantageous to identify higher throughput, in vitro models that could be used to give an earlier assessment of seizure liability. The hippocampal brain slice is one possibility but conventionally allows recording from only one slice at a time. The aim of this study was to validate a semi-automated system (Slicemaster, Scientifica UK Ltd) which allows concurrent electrophysiological recording from multiple brain slices. METHODS: Conventional electrophysiological recording techniques were used to record electrically evoked synaptic activity from rat hippocampal brain slices. Population spikes (PS) were evoked at 30 s intervals by electrical stimulation of the Schaffer collateral pathway and were recorded using extracellular electrodes positioned in the CA1 cell body layer. Responses were quantified as PS areas (the area above and below the 0 mV line). The effects of eight validation compounds known to cause seizures in vivo and/or in the clinic were assessed. RESULTS: Seven out of eight compounds evoked a concentration-dependent increase in population spike (PS) area that was statistically significant at higher concentrations (P<0.05; ANOVA). At the highest test concentration the percentage effects (mean+/-s.e.m.), relative to vehicle, were: picrotoxin 212.9+/-28.8, pentylenetrazole (PTZ) 181.4+/-24.7, 4-AP 328.9+/-48.6, aminophylline 124.5+/-5.9, chlorpromazine 122.1+/-9.8, SNC-80 132.1+/-12.6 and penicillin 174.7+/-14.1. Physostigmine had no significant effect on PS area although a concentration-dependent change in the morphology of the response was evident. DISCUSSION: All validation compounds evoked a statistically significant effect on synaptic activity in the rat hippocampal slice. Although similar effects have been described previously, this is the first time that the effects of a pharmacologically diverse set of compounds have been assessed using a standardised brain slice assay. Given the low compound usage and relatively high throughput associated with this assay, the hippocampal brain slice assay may facilitate earlier testing of convulsant liability than is currently possible using in vivo models.


Assuntos
Potenciais de Ação/fisiologia , Eletrofisiologia/métodos , Hipocampo/fisiologia , Convulsões/fisiopatologia , 4-Aminopiridina/toxicidade , Potenciais de Ação/efeitos dos fármacos , Animais , Benzamidas/toxicidade , Clorpromazina/toxicidade , Convulsivantes/classificação , Convulsivantes/toxicidade , Dimetil Sulfóxido/toxicidade , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/instrumentação , Avaliação Pré-Clínica de Medicamentos/métodos , Eletrofisiologia/instrumentação , Feminino , Hipocampo/efeitos dos fármacos , Técnicas In Vitro , Masculino , Penicilina G/toxicidade , Pentilenotetrazol/toxicidade , Fisostigmina/toxicidade , Picrotoxina/toxicidade , Piperazinas/toxicidade , Ratos , Ratos Wistar , Reprodutibilidade dos Testes , Convulsões/diagnóstico
16.
Arch Pharm (Weinheim) ; 334(5): 153-6, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11413820

RESUMO

A number of phenylamides of 5-benzamidopyrazole-4-carboxylic acid were prepared in 50-80% yields from 1-phenyl (or methyl)-6-phenylpyrazolo[3,4-d]1,3-oxazin-4(1H)-ones and aniline derivatives. All the compounds were tested for their analgesic and antiinflammatory activities, as well as for their ulcerogenic potential and acute toxicity. Some derivatives, when compared to phenylbutazone, proved more active in the tests for analgesic and antiexudative activities, but less active in the carrageenin paw oedema test. The compounds proved to posses marginal or no ulcerogenic effect, as well as low systemic toxicity.


Assuntos
Analgésicos/síntese química , Mediadores da Inflamação/síntese química , Tiazóis/síntese química , Analgésicos/farmacologia , Analgésicos/toxicidade , Animais , Benzamidas/química , Benzamidas/farmacologia , Benzamidas/toxicidade , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Mediadores da Inflamação/farmacologia , Mediadores da Inflamação/toxicidade , Masculino , Camundongos , Pirazóis/química , Pirazóis/farmacologia , Pirazóis/toxicidade , Ratos , Ratos Sprague-Dawley , Relação Estrutura-Atividade , Tiazóis/farmacologia , Tiazóis/toxicidade
17.
Cephalalgia ; 20(6): 538-45, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-11075836

RESUMO

The mechanistically novel benzopyran derivative SB-220453, which is undergoing clinical evaluation in migraine, exhibits a high affinity for a selective, but not yet characterized, binding site in the human brain. It inhibits nitric oxide release and cerebral vasodilatation following cortical spreading depression as well as carotid vasodilatation induced by trigeminal nerve stimulation in the cat. The aim of our study was to investigate the contractile properties of SB-220453 on a number of human isolated blood vessels (coronary artery, saphenous vein and middle meningeal artery) as well as atrial and ventricular cardiac trabeculae. While sumatriptan induced marked contractions in three blood vessels investigated, SB-220453 was devoid of any effect. In atrial and ventricular cardiac trabeculae, neither SB-220453 nor sumatriptan displayed a positive or negative inotropic effect. Since SB-220453 did not contract the middle meningeal artery, we conclude that potential anti-migraine effects are not mediated via a direct cerebral vasoconstriction. The lack of activity of SB-220453 in coronary artery, saphenous vein and cardiac trabeculae demonstrates that the compound is unlikely to cause adverse cardiac side-effects.


Assuntos
Analgésicos/farmacologia , Benzamidas/farmacologia , Benzopiranos/farmacologia , Contração Miocárdica/efeitos dos fármacos , Sumatriptana/farmacologia , Vasoconstrição/efeitos dos fármacos , Adulto , Idoso , Benzamidas/toxicidade , Benzopiranos/toxicidade , Vasos Coronários/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Átrios do Coração/efeitos dos fármacos , Ventrículos do Coração/efeitos dos fármacos , Humanos , Masculino , Artérias Meníngeas/efeitos dos fármacos , Pessoa de Meia-Idade , Norepinefrina/farmacologia , Veia Safena/efeitos dos fármacos
18.
Artigo em Russo | MEDLINE | ID: mdl-8820668

RESUMO

The damaging action of a number of bacterial toxins is determined by their capacity for blocking the specific functions of regulatory proteins of eukaryotic cells by ADP-ribosylation. Experiments, made with the use of type B botulinic toxin and 3,N-butyrylaminobenzamide as an example, have demonstrated that specific ADP-ribosylation inhibitors are capable of making up a new group of highly active antagonists of microbial toxins.


Assuntos
Anti-Infecciosos/uso terapêutico , Toxinas Bacterianas/antagonistas & inibidores , Benzamidas/uso terapêutico , Animais , Anti-Infecciosos/toxicidade , Benzamidas/toxicidade , Toxinas Botulínicas/antagonistas & inibidores , Toxinas Botulínicas/toxicidade , Botulismo/tratamento farmacológico , Botulismo/prevenção & controle , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Dose Letal Mediana , Masculino , Camundongos , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA